Craig-Hallum Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum has initiated coverage on SAB Biotherapeutics with a Buy rating and set a price target of $11.
October 09, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum has initiated coverage on SAB Biotherapeutics with a Buy rating and a price target of $11, indicating a positive outlook.
The initiation of coverage with a Buy rating and a price target of $11 by Craig-Hallum suggests a positive outlook for SAB Biotherapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100